| $350M | ||
| $241M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $162,244 | 5 | 100 |
Sells | $0 | 0 | 0 |
| Luo Peter | Chief Executive Officer | 3 | $148,744 | 0 | $0 | $148,744 |
| DO CUONG V | director | 1 | $7,500 | 0 | $0 | $7,500 |
| Tam Man Kin | Chief Financial Officer | 1 | $6,000 | 0 | $0 | $6,000 |
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
Over the last 12 months, insiders at Adagene Inc. have bought $162,244 and sold $0 worth of Adagene Inc. stock.
On average, over the past 5 years, insiders at Adagene Inc. have bought $162,244 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Luo Peter (Chief Executive Officer) — $148,744. DO CUONG V (director) — $7,500. Tam Man Kin (Chief Financial Officer) — $6,000.
The last purchase of 2,000 shares for transaction amount of $6,000 was made by Tam Man Kin (Chief Financial Officer) on 2026‑09‑23.
| 2026-09-23 | Tam Man Kin | Chief Financial Officer | 2,000 0.0054% | $3.00 | $6,000 | -14.31% | ||
| 2026-09-16 | Luo Peter | Chief Executive Officer | 20,290 0.0536% | $3.15 | $63,980 | -15.46% | ||
| 2026-08-14 | DO CUONG V | director | 2,000 0.0045% | $3.75 | $7,500 | -19.73% | ||
| 2026-08-05 | Luo Peter | Chief Executive Officer | 279 0.0006% | $3.65 | $1,018 | -24.35% | ||
| 2026-08-04 | Luo Peter | Chief Executive Officer | 22,966 0.0611% | $3.65 | $83,746 | -12.09% |
| Increased Positions | 8 | +40% | 1M | +21.74% |
| Decreased Positions | 7 | -35% | 4M | -67.74% |
| New Positions | 4 | New | 1M | New |
| Sold Out Positions | 4 | Sold Out | 4M | Sold Out |
| Total Postitions | 21 | +5% | 3M | -46.01% |